BrightSpring Health Services, Inc. Common Stock (BTSG) Stock Analysis

Research · Sep 3, 2026

BTSGU: FY25 Deep Dive

BrightSpring Health TEU. FY25 (underlying) $12.91B revenue (+15%). NI $191M.

Research · Sep 3, 2026

[BTSG] BrightSpring Health Services Thesis 2026: Pharmacy Cycle Drives Home Healthcare Conversion

BrightSpring Health Services, Inc. (NASDAQ: BTSG) FY2025 revenue ~$12.0-12.6B (+20-26%) with adj. EPS ~$1.10-1.30 reflecting continued post-2024 ~$10.2-10.7B aggregate Pharmacy Solutions revenue (~85%+ aggregate revenue mix; selected primary Specialty + Infusion + Home + LTC + selected various aggregate Pharmacy + selected various aggregate post-2024 Onco360 specialty oncology) + selected continued post-2024 ~$1.85-1.95B aggregate Provider Services revenue (~15% aggregate revenue mix; selected primary Home Healthcare + Hospice + Personal Care + selected various aggregate Behavioral Health) under continued President + CEO Jon Rousseau since 2014 (~11-year tenure as BrightSpring CEO; selected post-January 2024 NYSE IPO). One of the largest US Home Healthcare + Pharmacy Services + Provider Services companies. Founded 2003 as ResCare Inc. by Ronald Geary in Louisville Kentucky (~22-year heritage); selected post-March 2019 ~$1.4B+ KKR + Walgreens Boots Alliance leveraged buyout; selected post-January 2024 NASDAQ IPO ($693M IPO proceeds); selected post-2024 Onco360 specialty oncology pharmacy acquisition; selected post-2014 Jon Rousseau CEO appointment. Headquartered in Louisville Kentucky; ~50,000+ employees globally with ~$12.0-12.6B revenue. Two primary business segments: Pharmacy Solutions (~85%+ ~$10.2-10.7B), Provider Services (~15% ~$1.85-1.95B). Geographic mix: US ~100%; selected primary 50-state US footprint. Pharmacy cycle (Specialty + Infusion + Home + LTC): ~$10.2-10.7B Pharmacy Solutions revenue; selected primary Specialty Rx (oncology + Onco360) + Infusion + Home + LTC; ~+25-30% aggregate Pharmacy Solutions revenue growth. Home Healthcare + Hospice + Personal Care conversion: ~$1.85-1.95B Provider Services revenue; selected primary Home Healthcare + Hospice + Personal Care + Behavioral Health; ~50-60% aggregate Medicare + Medicaid mix. President + CEO Jon Rousseau since 2014 (~11-year tenure); CFO Jim Mattingly. Capital position: ~$0 dividend (no dividend track post-January 2024 NYSE IPO); minimal opportunistic buybacks; ~$0.4-0.5B aggregate cash + investments balance; net leverage ratio ~4.0-4.5x; non-investment grade B1/B+ credit rating; selected ~70%+ aggregate KKR + Walgreens Boots Alliance + selected various aggregate ownership concentration. FY2026 thesis: Pharmacy cycle (Specialty + Infusion + Home + LTC + Onco360 oncology) + Home Healthcare + Hospice + Personal Care conversion + selected post-January 2024 NYSE IPO + selected projected post-2026 deleveraging + selected ~70%+ KKR + Walgreens parent ownership concentration. Risks: CVS Health Specialty + Caremark + Optum Specialty + Express Scripts + Option Care Health competition, Encompass Health + Pennant Group + Amedisys + Addus HomeCare + LHC Group competition, CMS Specialty Rx + Home Healthcare + Hospice reimbursement, sustained ~4.0-4.5x net leverage.